HINDUSTAN BIO SCIENCES LTD.

Hindustan Bio Sciences Ltd has announced the closure of its trading window for dealing in the company's securities. The window will be shut from July 01, 2026, until 48 hours after the announcement of the Standalone Un-Audited Financial Results for the quarter ending June 30, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal codes. The company has also ensured the freezing of PANs for designated persons and their immediate relatives during this period. The date for the Board Meeting to declare these financial results will be communicated separately.

Hindustan Bio Sciences Ltd's board approved the audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The company reported revenue from operations of ₹73.71 Cr for the year ended March 31, 2026, compared to ₹81.33 Cr in the previous year. The board also approved the appointment of Mr. GBK Viswanadham as an Internal Auditor for the financial year 2026-27.

Hindustan Bio Sciences Ltd's board meeting on May 30, 2026, approved the appointment of Mr. GBK Viswanadham as the Internal Auditor for the financial year 2026-27, based on the Audit Committee's recommendations. The board also approved the audited standalone financial results for Q4 and the financial year ended March 31, 2026, along with the audit report. The meeting commenced at 02:00 P.M. and concluded at 3:00 P.M.

Hindustan Bio Sciences Ltd's Board of Directors approved the audited standalone financial results for the fourth quarter and financial year ended March 31, 2026. The company reported revenue from operations of ₹73.71 Cr for the year ended March 31, 2026, compared to ₹81.33 Cr in the previous year. The board also approved the appointment of Mr. GBK Viswanadham as the Internal Auditor for the financial year 2026-27.

Hindustan Bio Sciences Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results for the quarter and year ended March 31, 2026, along with the audit report for the same period. The meeting will be held at the company's registered office in Hyderabad.

Hindustan Bio Sciences Ltd has announced that the trading window for dealing in the securities of the company will be closed from April 01, 2026 till 48 hours after the announcement of Standalone Audited Financial results for the Year ending on March 31, 2026. This closure is as per the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the Company's Code of Conduct for regulating, monitoring, and reporting trading by Insiders and Code of Practices and Procedures for fair disclosure of Unpublished Price Sensitive Information. The date of the Board Meeting for the declaration of the Standalone Audited Financial results will be intimated in due course.

Hindustan Bio Sciences Ltd has announced its un-audited financial results for the quarter ended 31-12-2025. The company's revenue from operations has grown by 31% YoY. The Board of Directors took these results on record in their meeting on 31st January 2026. The company's total expenses for the quarter stood at INR XX.XX Crores, leading to a profit before tax of INR XX.XX Crores. The company's earnings per equity share for continuing operations were INR XX.XX for the basic and diluted categories.

Hindustan Bio Sciences Ltd. held a Board Meeting on January 31, 2026, where they approved the un-audited financial results for the quarter ended 31st December 2025. The company's revenue from operations, total revenue, and profit before tax have been reported. The meeting also reviewed the Limited Review Report for the quarter ended 31st December 2025.

Bosco Armando Menezes and Emily Bosco Menezes have revised their disclosure under the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for the purchase of shares in Hindustan Bio Sciences Ltd. The revised disclosure corrects an inadvertent error in the original disclosure regarding the equity share capital of the target company.

Hindustan Bio Sciences Ltd has disclosed the acquisition of shares by BOSCO MENEZES under SAST regulation 29(2). The acquisition was made through the open market. Before the acquisition, BOSCO MENEZES held 2.49% shares carrying voting rights and 2.49% shares in the nature of encumbrance. After the acquisition, his holding of shares carrying voting rights increased to 2.53%. The total share capital of the company is Rs. 2,05,01,600/- constating of 1,02,50,800 Equity share capital / total voting capital.